Found: 2
Select item for more details and to access through your institution.
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 12, p. 1523, doi. 10.1007/s00262-016-1904-8
- By:
- Publication type:
- Article
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
- Published in:
- Cancer Immunology, Immunotherapy, 2016, v. 65, n. 9, p. 1047, doi. 10.1007/s00262-016-1864-z
- By:
- Publication type:
- Article